MARKET

FOLD

FOLD

Amicus Therapeut
NASDAQ
13.53
+0.13
+0.97%
After Hours: 13.64 +0.11 +0.81% 16:26 02/23 EST
OPEN
13.48
PREV CLOSE
13.40
HIGH
13.64
LOW
13.41
VOLUME
7.67M
TURNOVER
0
52 WEEK HIGH
14.57
52 WEEK LOW
9.70
MARKET CAP
3.97B
P/E (TTM)
-22.7319
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at FOLD last week (0212-0216)?
Weekly Report · 5d ago
Amicus Therapeut: Report of proposed sale of securities
Press release · 02/16 00:36
Amicus Therapeut: [Amend]Statement of acquisition of beneficial ownership by individuals
Press release · 02/14 15:05
Weekly Report: what happened at FOLD last week (0205-0209)?
Weekly Report · 02/12 10:08
Weekly Report: what happened at FOLD last week (0129-0202)?
Weekly Report · 02/05 10:13
Weekly Report: what happened at FOLD last week (0122-0126)?
Weekly Report · 01/29 10:07
Amicus Therapeut: [Amend]Statement of acquisition of beneficial ownership by individuals
Press release · 01/26 20:04
Amicus Therapeut: Statement of changes in beneficial ownership of securities
Press release · 01/25 06:02
More
About FOLD
Amicus Therapeutics, Inc. is a biotechnology company that is focused on discovering, developing, and delivering medicines for rare diseases. The Company's portfolio is Galafold (migalastat), which is the approved oral precision medicine for people living with Fabry disease. Galafold is designed to bind to and stabilize an endogenous alpha-galactosidase A (alpha-Gal A) enzyme in patients with genetic variants. Migalastat is approved under the trade name Galafold in the United States, European Union, United Kingdom and Japan. Its biologics program in its pipeline is Amicus Therapeutics GAA (AT-GAA), which is a clinical-stage treatment paradigm for Pompe disease. Pompe disease is a lysosomal disorder (LD) from deficiency in an enzyme, GAA. AT-GAA consists of a uniquely engineered rhGAA enzyme, ATB200, or cipaglucosidase alfa, with an optimized carbohydrate structure to enhance lysosomal uptake, administered in combination with AT2221 (miglustat) that functions as an enzyme stabilizer.

Webull offers Amicus Therapeutics, Inc. stock information, including NASDAQ: FOLD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FOLD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading FOLD stock methods without spending real money on the virtual paper trading platform.